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Objective. To test the association of osteopontin
(OPN) polymorphisms with systemic lupus erythemato-
sus (SLE).
Methods. The coding 5 and 3 flanking regions of
the OPN gene were scanned for polymorphisms by
denaturing high-performance liquid chromatography. A
case–control association study was performed in 394
Italian SLE patients and 479 matched controls. OPN
serum levels were determined by enzyme-linked immu-
nosorbent assay in 40 patients and 124 controls, and the
mean levels were compared between the different OPN
genotypes.
Results. Among the 13 detected single-nucleotide
polymorphisms (SNPs), alleles 156G (frequency 0.714
versus 0.651; P  0.006, corrected P [Pcorr]  0.036)
and 1239C (0.377 versus 0.297; P  0.00094, Pcorr 
0.0056) were significantly increased in the SLE patients
compared with the controls. The presence of the asso-
ciated allele in single or double dose conferred an odds
ratio (OR) of 2.35 (95% confidence interval [95% CI]
1.38–4.02) for SNP 156 and an OR of 1.57 (95% CI
1.16–2.13) for SNP 1239. These effects were indepen-
dent of each other, i.e., not a consequence of linkage
disequilibrium between the 2 alleles. The risk associated
with a double dose of susceptibility alleles at both SNPs
was 3.8-fold higher (95% CI 2.0–7.4) relative to the
complete absence of susceptibility alleles. With regard
to individual clinical and immunologic features, a sig-
nificant association was seen between lymphadenopathy
and 156 genotypes (overall P  0.0011, Pcorr  0.046).
A significantly increased OPN serum level was detected
in healthy individuals carrying 1239C (P  0.002),
which is indicative of an association between the SLE
susceptibility allele and OPN levels.
Conclusion. These data suggest the independent
effect of a promoter (156) and a 3-untranslated
region (1239) SNP in SLE susceptibility. We can
speculate that these sequence variants (or others in
perfect linkage disequilibrium) create a predisposition
to high production of OPN, and that this in turn may
confer susceptibility to SLE.
Systemic lupus erythematosus (SLE) is an auto-
immune disease with a multifactorial etiology that is
characterized by impaired T cell responses and dysregu-
lation of B cell activation, leading to B cell hyperactivity
and production of autoantibodies. Several lines of evi-
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dence suggest that early T cell activation gene 1, or
osteopontin (OPN), may have a role in the pathogenesis
of SLE as well as other autoimmune disorders.
OPN is a 60-kd secreted phospho-protein func-
tioning as a free cytokine in body fluids or as an
immobilized extracellular matrix molecule in mineral-
ized tissues (1,2). OPN may influence autoimmune
diseases through its immunoregulatory effects, enhanc-
ing the proinflammatory Th1 cell response and inhibit-
ing the Th2 responses (3,4). Moreover, OPN stimulates
T cell proliferation, interferon- production, and CD40
ligand expression, which in turn sustains the prolifera-
tion of B cells and production of antibodies (5). In mice,
transgenic overexpression of OPN on a nonautoimmune
background produces an autoimmune pattern with ac-
cumulation of B1 lymphocytes, hypergammaglobuline-
mia, and production of autoantibodies, including anti–
double-stranded DNA antibodies (6). In humans, the
serum level of OPN is increased in patients with SLE
(7), and lupus nephritis is associated with increased
OPN expression in renal tissue (8,9). A synonymous
sequence variation in exon 7 (Ala236Ala) of the OPN
gene was significantly associated with SLE in a sample of
81 American patients with SLE (10).
A pathogenetic role of OPN has been strongly
suggested in MRL-lpr/lpr mice (11–14) and in patients
affected by the autoimmune lymphoproliferative syn-
drome (ALPS) (15); in both mice and patients with
ALPS, an autoimmune pattern partially similar to SLE
develops, associated with hypergammaglobulinemia,
lymphadenopathy and/or splenomegaly, and peripheral
expansion of CD4/CD8 double-negative T cells. In both
mice and humans, the disease has been attributed to
inherited mutations targeting the function of the Fas
death receptor involved in switching of the immune
response (16,17). Several studies have suggested that
high OPN levels contribute to the disease. Observations
in mice revealed that 1) CD4/CD8 double-negative T
cells constitutively expressed high levels of OPN, and
this elevation of OPN coincided with the appearance of
immunologic abnormalities (11–13), and 2) onset of
polyclonal B cell activation was delayed by crossing
MRL-lpr/lpr with opn/ mice (13,14), while observa-
tions in humans demonstrated that 3) high OPN levels
directly correlated with hypergammaglobulinemia (15),
and 4) 2 SNPs in the OPN 3-untranslated region
(3-UTR) (1083A/G and 1239A/C) were associated
with high production of OPN and increased the risk of
ALPS by 8-fold (15). Intriguingly, families of ALPS
patients display an increased frequency of several com-
mon autoimmune diseases, including SLE, which sug-
gests that they carry an autoimmune-prone genetic
background.
The present study sought to test the involvement
of OPN in SLE. To this purpose, the coding 5 and 3
flanking regions of the OPN gene were screened for
sequence variations in SLE patients. The identified
SNPs were tested for an association with SLE in a large
panel of Italian patients and controls. The frequencies of
the associated SNPs were then compared in patient
subsets subdivided according to their clinical and immu-
nologic features. Finally, the association of SLE-
associated OPN genotypes with OPN serum production
was investigated.
PATIENTS AND METHODS
Subjects. A total of 394 Italian patients with SLE (7.5:1
female:male ratio) were included in this study. All patients
fulfilled 4 of the American College of Rheumatology 1997
revised criteria for the classification of SLE (18). Enrollment
was completed when the patients provided their informed
consent. The clinical and immunologic features of the SLE
patients are shown in Table 1. A random panel of 479
Table 1. Clinical and immunologic features of the patients with
SLE*
Feature % of patients
Clinical manifestation
Malar rash 40
Photosensitivity 35
Discoid lesion 12
Serositis† 30
Oral ulcers 27
Arthritis 65
Glomerulonephritis 31
Autoimmune hemolytic anemia 11
Raynaud’s phenomenon 32
Lymphadenopathy 17
Leukopenia and/or lymphopenia‡ 53
Thrombocytopenia§ 23
Neurologic involvement¶ 16
Antiphospholipid syndrome 9
Autoantibodies
ANA 89
Anti-dsDNA 76
Anti-La(SSB) 6
Anti-Ro(SSA) 23
Anti-RNP and/or Sm 23
Antiphospholipids# 31
Rheumatoid factor 19
* SLE  systemic lupus erythematosus; ANA  antinuclear antibod-
ies; anti-dsDNA  anti–double-stranded DNA.
† Includes pericarditis and/or pleuritis.
‡ Leukocyte count 4,000/mm3; lymphocyte count 1,500/mm3.
§ Platelet count 100,000/mm3.
¶ Includes seizures and/or psychosis and/or transient ischemic attack.
# Presence of anticardiolipin antibodies and/or lupus anticoagulant
activity.
540 D’ALFONSO ET AL
Caucasian individuals from Italy (comprising medical students,
university and hospital staff, and blood donors) were used as
control subjects (2.6:1 female:male ratio). The regional origin
of the patients and controls was similar and included 65% of
individuals residing in northern Italy and the remaining in
central-southern Italy. Individuals with Sardinian ancestors
were excluded.
Search for sequence variations in the OPN gene. The
OPN gene was amplified from genomic DNA as 12 polymerase
chain reaction (PCR) fragments covering a total of 4,401 bp,
including the 7 exons, the intron-exons boundaries, 2,083 bp
upstream of the transcription start site, and 383 bp in the
3-UTR region. PCR primers were designed on the genomic
DNA GenBank sequence D14813 (version GI: 506341). The
search for sequence variations was performed by denaturing
high-performance liquid chromatography (DHPLC) on an
automated HPLC instrument (WAVE; Transgenomic, Santa
Clara, CA) as previously reported (19).
The temperature required for successful resolution of
heteroduplex molecules was determined using a specific pro-
gram (available at the Web site http://insertion.stanford.edu/
melt.html). Samples were analyzed at the predicted tempera-
tures (RTm) and at RTm 2°C, as recommended by the
software authors (20), and were eluted from the column using
a linear acetonitrile gradient at a constant flow rate of 0.9
ml/minute. The gradient was created by mixing elution buffers
A (0.1M triethylamine acetate buffer [TEAA], pH 7) and B
(25% acetonitrile in 0.1M TEAA, pH 7). The start and end
points of the gradient depended on the size of the PCR
fragments. Primers used for amplification and DHPLC condi-
tions are available from the authors upon request. The PCR
products displaying a heteroduplex peak were sequenced and
compared with the sequence of a homozygous sample.
Sequencing. Prior to sequencing, unincorporated
dNTPs and primers were removed by 0.5 units of shrimp
alkaline phosphatase and 5 units of exonuclease I (both from
Amersham, Arlington Heights, IL) at 37°C for 30 minutes,
after which the enzymes were inactivated by incubation at 80°C
for 15 minutes. Samples were sequenced in both directions on
an Applied Biosystems 3100 Genetic Analyzer using the Big-
Dye terminator cycle-sequencing reaction kit (Applied Biosys-
tems, Foster City, CA).
Genotyping of OPN SNPs. In a preliminary screening
on a small panel of patients and controls, all of the detected
SNPs were genotyped by primer extension followed by HPLC
analysis on the WAVE (Transgenomic) instrument (21). The 6
SNPs selected after this analysis were tested on a larger panel
by the SNaPshot method on an ABI 3100 Genetic Analyzer
(Applied Biosystems). Because of random technical reasons,
different numbers of individuals, ranging from 366 to 394
patients and from 420 to 479 controls, were genotyped for each
SNP. Two SNaPshot reactions were designed, one for the 4
SNPs in the 5 region (616G/T, 443T/C, 156G/GG,
66T/G) amplified in the same amplicon, and one for the 2
SNPs in the 3 region (1083A/G and 1239A/C), also
amplified in one fragment. Samples were electrophoresed on
the ABI 3100 Genetic Analyzer. Resulting electropherograms
were analyzed using ABI GeneScan, version 3.7 software.
SNaPshot conditions are available from the authors upon
request.
Enzyme-linked immunosorbent assay (ELISA). Serum
OPN concentrations were evaluated by a capture ELISA in
accordance with the protocol provided by the manufacturer
(Calbiochem, La Jolla, CA). The optical density was measured
at 450 nm with a microplate reader (Bio-Rad, Hercules, CA).
The I-smart program was used to create a regression curve.
Statistical analysis. The statistical significance of the
difference in gene and genotype frequencies between patients
and controls was evaluated for each polymorphism using the
chi-square test with Yates’ correction. When required by the
small number of expected cases, Fisher’s 2-tailed exact test was
used. When specified, P values were corrected (Pcorr) for the
number of comparisons, according to the Bonferroni method.
Maximum-likelihood estimation of haplotype frequen-
cies and corresponding standard deviations were calculated
from data with unknown gametic phase, using an expectation-
maximization (EM) algorithm (Arlequin, version 2.0 [22]). The
significance of the difference in single haplotype frequencies
between patients and controls was evaluated by analyzing the
standard deviation, in which a P value of less than 0.05
corresponds to patient/control haplotype frequencies that do
not overlap when considering frequencies of 2 SD. The
significance of the overall difference in haplotype frequencies
between patients and controls was evaluated by estimating the
value as follows: L (L1 L2) L3, where L1, L2, and L3 are
the 2 log likelihood estimated in the patients (L1), the
controls (L2), and patients  controls (L3). The L value
follows a chi-square distribution with degrees of freedom (df)
corresponding to the total number of estimated haplotypes1.
Pairwise linkage disequilibrium was evaluated by calculating
the D (23) and r2 (24) values.
The association of each polymorphism with the disease
was measured by the odds ratio (OR) and its 95% confidence
interval (95% CI), while the joint effect of different polymor-
phisms was tested by multivariate logistic regression (25) using
SAS Proc Logistic (SAS Institute, Cary, NC). The departure of
the observed ORs from those predicted under additivity of
effects (additive-effects model) was measured by computing
the RERI index and its 95% CI (26). The departure from a
multiplicative model was tested by inclusion of an interaction
term in the logistic regression model (27). In addition, data
were made to fit a parametric model (reparametrization) by
creating a set of dummy variables for the different possible
combinations of genotypes (26); this procedure was used for
descriptive purposes (as in Table 6), for computing the RERI
as suggested by Hosmer and Lemeshow (26), and also for
estimating the departure from a multiplicative model when the
product term could not fit because of lack of data.
The distribution of OPN serum levels in the study
population was right-skewed. A logarithmic transformation of
the OPN serum levels was introduced to approximate a normal
distribution. Relevant comparisons were performed using Stu-
dent’s t-test.
RESULTS
Analysis of the OPN gene-sequence variations.
The 7 exons, the exon-intron boundaries, 2,083 bp of the
5 flanking region, and 383 bp of the 3-UTR of the OPN
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gene were screened for sequence variations by DHPLC
in 23 SLE patients. A total of 13 SNPs were identified (6
in the 5 flanking region, 1 in intron 3, 3 synonymous
variations in exons 6 and 7, and 3 in the 3-UTR) (Table
2). Five of these SNPs were newly identified, whereas
the remaining were previously reported in the literature
(28,29) or in SNP databases.
About 70 patients and 100 controls were then
genotyped for all of the SNPs reported in Table 2 and, in
addition, for a recently published TG/TGTG biallelic
polymorphism in the first intron (30). Four SNPs
(namely, 1282A/G, IV342A/C, 351T/C, and
1158A/G) with a minor allele frequency of 3% in
both patients and in controls were not tested further.
SNPs at positions 282, 750, and 1239 showed a
perfect linkage disequilibrium between each other, and
therefore given the redundant genetic information, only
1 of them, namely 1239A/C, was further considered.
The same was true for 1748A/G, 156G/GG, and the
intron 1 polymorphism, and consequently, only
156G/GG was further considered.
Thus, starting from 14 validated SNPs, a set of 6
SNPs was further tested with a larger panel. A significant
pairwise linkage disequilibrium was observed among
these 6 SNPs, as shown in the healthy controls (Table 3);
similar values were also observed in the patients (data
Table 2. Osteopontin single-nucleotide polymorphisms (SNPs) identified in patients with systemic lupus erythematosus*
Variation Location Sequence
No. of
heterozygotes Accession no. (ref.)†
1748A/G‡ 5flanking aattttcA/Ggacttcc 7 rs2728127 (28)
1282A/G‡ 5flanking tagtccaA/Gtctgcat 1 This study
616G/T‡ 5flanking tcatcctG/Tctctcag 4 rs2853744 (28)
443T/C‡ 5flanking gcaagttT/Ctctgaac 10 (28)
156G/GG‡ 5flanking cgtttttG/GGttttttt 7 rs7687316 (28)
66T/G‡ 5flanking caatctcT/Gccgcctc 5 This study
IV342A/C§ Intron 3 tccctacA/Ctttcttt 1 This study
282T/C (Asp80Asp)¶ Exon 6 atgatgaT/Cgaccatg 14 rs4754 (29)
351T/C (Thr103Thr)¶ Exon 6 ttttcacT/Cccagttg 2 This study
750 C/T (Ala236Ala)¶ Exon 7 ggaaagcC/Taatgatg 14 rs11226616 (29)
1083A/G¶ 3-UTR aataactA/Gatgtgtt 11 rs1126772 (29)
1158A/G¶ 3-UTR tatgtctA/Gtgttcat 1 This study
1239A/C¶ 3-UTR atgtagaA/Cgcaaaca 14 rs9138 (29)
* Sequence variations are shown in upper case. Heterozygotes were detected by denaturing high-performance liquid
chromatography in 23 patients.
† Accession number in the National Center for Biotechnology Information SNP data bank (http://www.ncbi.nlm.nih.gov/SNP).
Thirteen additional SNPs are reported in the database in the sequences screened in this report (namely, rs3891314, rs2853745,
rs2853747, rs2859696, rs2728128, rs2853748, rs2859697, rs4660, rs1126859, rs112688, rs1126893, rs6812524, and rs7435825), but
these were not detected in the tested individuals.
‡ Numbering is relative to the transcription start site (1) corresponding to nucleotide 2268 in the GenBank sequence number
D14813 (GI: 506341).
§ Numbering is relative to the last (1) nucletotide of intron 3.
¶ Position in the cDNA considering the A nucleotide of the first ATG as 1.
Table 3. Pairwise linkage disequilibrium (LD) between osteopontin single-nucleotide polymorphisms in controls*
Allele 616 (G) 443 (C) 156 (G) 66 (T) 1083 (G) 1239 (C)
616 (G) 0.125 0.259 NS† 0.053 0.072
443 (C) 1.00‡ 0.519 0.317 0.229 0.134
156 (G) 1.00‡ 1.00‡ 0.660 0.185 0.232
66 (T) NS† 1.00‡ 1.00‡ 0.104 0.146
1083 (G) 1.00§ 0.861‡ 0.966‡ 0.929‡ 0.687
1239 (C) 1.00§ 0.524‡ 0.942‡ 0.942‡ 1.00‡
* Values for r2 and D (Lewontin D values) are reported in the upper-right triangle and lower-left triangle of the table,
respectively. All values refer to the variant allele indicated in parentheses. A minimum of 345 individuals were analyzed for each
comparison. All r2 values 0.5 and D values 0.95 are shown in boldface.
† Linkage disequilibrium between66T and616G was not significant (NS). A significant linkage disequilibrium was detected
between 66T and the 616T allele (P  0.006, D  1, r2  0.045) (not shown).
‡ P  0.05.
§ P  0.001.
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not shown). The frequency of the 7 haplotype combina-
tions, accounting for 98% of the total (Table 4), were
estimated in both patients and controls by the maximum-
likelihood method based on the EM algorithm (22).
Association with SLE susceptibility. The overall
haplotype distribution was significantly different be-
tween patients and controls (P 0.024, 11 df). However,
none of the specific haplotype frequencies was signifi-
cantly distorted. The haplotype showing the highest
frequency in the patients (haplotype 7 in Table 4)
carried alleles that were all individually increased in the
patients. The association with SLE was significant for 3
of the alleles, namely, 156G (frequency in SLE pa-
tients versus controls 0.714 versus 0.651; P  0.0060,
Pcorr  0.036), 1083G (0.303 versus 0.244; P  0.0077,
Pcorr  0.046), and 1239C (0.377 versus 0.297; P 
0.00094, Pcorr  0.0056), withstanding Bonferroni cor-
rection for the number of tested SNPs (n  6). For
simplicity, alleles significantly increased in the patients
(156G, 1083G, and 1239C) were named 1 (i.e.,
susceptibility alleles), whereas alleles significantly de-
creased in the patients (156GG, 1083A, and
1239A) were named 0 (i.e., protective alleles).
The genotype distribution at the 3 positions
(Table 5) was significantly different between patients
and controls. The presence of the disease-associated
allele, in single or in double dose, conferred an OR of
2.35 (95% CI 1.38–4.02) for SNP 156, an OR of 1.56
Table 4. Estimated SNP haplotype combinations in patients with SLE and controls*
Haplotype 616 443 156 66 1083 1239
SLE (n  330)† Controls (n  345)†
Frequency
Standard
deviation Frequency
Standard
deviation
1 G T GG G A A 0.183 0.0134 0.224 0.0169
2 T T GG T A A 0.078 0.0089 0.102 0.0104
3 G T G T A A 0.115 0.0138 0.118 0.0116
4 G C G T A A 0.241 0.0176 0.246 0.0146
5 G T G T A C 0.062 0.0095 0.043 0.0065
6 G T G T G C 0.020 0.0073 0.020 0.0053
7 G C G T G C 0.280 0.0193 0.227 0.0183
* The displayed 7 haplotypic combinations account for 98% of the total haplotype frequencies. The remaining 2% were
distributed in 5 rare haplotypes in both patients and controls. SLE  systemic lupus erythematosus.
† Number of individuals tested with the complete set of the 6 selected single-nucleotide polymorphisms (SNPs).
Table 5. Genotype distribution in patients with SLE and controls for osteopontin SNPs 156, 1083,
and 1239*
SNP site,
genotype†
SLE, %
(n  330)‡
Controls, %
(n  401)‡
Crude OR
(95% CI)
Adjusted OR
(95% CI)§
156
00 0.07 0.15 1.00 (referent) 1.00 (referent)
01 0.40 0.40 2.19 (1.29–3.73) 1.95 (1.12–3.38)
11 0.53 0.45 2.58 (1.53–4.35) 2.04 (1.16–3.59)
1083
00 0.49 0.60 1.00 (referent) 1.00 (referent)
01 0.40 0.33 1.46 (1.07–2.00) 1.08 (0.63–1.85)
11 0.11 0.07 1.82 (1.08–3.06) 0.80 (0.27–2.34)
1239
00 0.40 0.51 1.00 (referent) 1.00 (referent)
01 0.45 0.39 1.49 (1.09–2.04) 1.21 (0.70–2.10)
11 0.15 0.10 2.07 (1.29–3.33) 2.03 (0.74–5.56)
* Odds ratios (ORs) and 95% confidence intervals (95% CIs) are relative to the referent genotype. See
Table 4 for other definitions.
† Alleles significantly increased in the patients (156G,1083G, and1239C) are named 1, while alleles
significantly decreased in the patients (156GG, 1083A, and 1239A) are named 0.
‡ The total comprises the number of tested individuals. Only individuals tested for all 3 SNPs are included.
Genotypes were distributed according to Hardy-Weinberg equilibrium.
§ Calculated with the use of a multivariate logistic regression analysis adjusted for 156, 1083, and
1239 SNPs. Results adjusted for the remaining 2 SNPs are reported for each SNP.
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(95% CI 1.15–2.12) for SNP 1083, and an OR of 1.57
(95% CI 1.16–2.13) for SNP 1239. For each SNP, a
double dose conferred a higher OR than a single dose,
but the difference was not statistically significant. A
multivariate analysis (Table 5) adjusted for genotypes at
positions1239 and156 indicated that1083 was not
an independent susceptibility factor (adjusted OR
1.00). Conversely, the OR conferred by 156 and
1239 after adjustment for the other 2 polymorphisms
remained similar to the crude OR, although the OR for
1239 was no longer statistically significant. This analy-
sis suggests that each of these 2 SNPs, one in the 5
flanking region and the other in the 3-UTR, contributes
to susceptibility independent of their linkage disequili-
brium relationship.
In order to fully describe the effect of the differ-
ent combinations of the 5 and the 3 sequence varia-
tions, we analyzed the ORs for all of their possible
genotype combinations (Table 6). Due to linkage dis-
equilibrium, 6 genotype combinations accounted for
99% of the samples. Two rare combinations accounted
for the remaining 1%. The overall distribution was
significantly different between patients and controls
(P  0.0069). Relative to the 00 genotype (absence of
susceptibility allele) at both SNPs, all of the other
genotype combinations conferred a significantly in-
creased OR. The highest OR was observed in individuals
homozygous for allele 1 at both SNPs (OR 3.82, 95% CI
2.0–7.4). More precisely, the risk conferred by each
genotype carrying 1 or 2 susceptibility alleles at position
156 increased with an increasing number of the 1239
susceptibility allele. The complementary analysis was
not possible, since 1239-1 was present only in haplo-
types also carrying 156-1 (Table 4).
We tested whether this pattern was better ex-
plained by an additive model as compared with a
multiplicative model, by comparing the observed ORs
with those predicted under additivity of effects
(additive-effects model) and with those predicted under
a multiplicative model. Departure from additivity was
measured by the RERI index and its 95% CI (26).
Departure from a multiplicative scale was tested by
comparing a model including 156 and 1239 suscep-
tibility alleles without interaction and a reparametrized
model as in Table 6 (see ref. 26 for details on parame-
trization). This latter procedure was used since a prod-
uct term could not fit because of the absence of some
relevant combinations due to linkage disequilibrium.
However, these analyses did not detect a departure of
the results from those predicted by either an additive or
a multiplicative model, so that the best model to de-
scribe the combined effect of the 2 genotypes remains
uncertain.
Association with disease features. Genotype fre-
quencies of the 156 and 1239 SNPs were compared
between patients who were positive or negative for each
of the clinical and immunologic features shown in Table
1. A statistically significant association, withstanding
correction for the number of comparisons (n  21
clinical and immunologic features  2 SNPs), was
detected only for the 156 polymorphism with the
presence of lymphadenopathy (overall P  0.0011;
Pcorr  0.046). The frequencies of 156-11, -01, and -00
genotypes were 0.714, 0.238, and 0.048, respectively, in
the 63 patients with lymphadenopathy and 0.458, 0.472,
and 0.070, respectively, in the 286 patients without
lymphadenopathy.
Table 6. Association of SLE susceptibility with different genotype combinations for the 3 (1239) and
5 (156) SNPs*
Genotype
combination†
No. of subjects with
combination
OR (95% CI)‡ P†1239 156 SLE Controls
00 00 21 59 1.00 (referent) –
00 01 62 86 2.03 (1.2–3.7) 0.02
00 11 48 61 2.21 (1.2–4.1) 0.01
01 01 70 74 2.66 (1.5–4.8) 0.001
01 11 77 82 2.64 (1.5–4.7) 0.001
11 11 49 36 3.82 (2.0–7.4) 0.0001
* See Tables 4 and 5 for definitions.
† Alleles significantly increased in the patients (156G and 1239C) are named 1, while alleles
significantly decreased in the patients (156GG and 1239A) are named 0. Two further rare
combinations were detected: genotypes 1239-11, 156-01 (1 patient and 2 controls), and 1239-01,
156-00 (2 patients and 2 controls):
‡ Relative to the referent genotype.
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Correlation with OPN serum levels. In order to
investigate a possible functional basis for the observed
genetic association, we analyzed OPN protein produc-
tion. OPN serum levels measured by ELISA were sig-
nificantly higher in 40 SLE patients than in 124 controls
(mean  SD of logarithm-transformed values 5.32 
0.55 ng/ml versus 4.94  0.53 ng/ml, corresponding to a
geometric mean of 204.8 ng/ml versus 140.1 ng/ml; P 
0.001). We then analyzed the association of OPN geno-
types with OPN protein levels in the serum. In a
previous study, we reported that among 50 healthy
controls, individuals carrying the1239C allele (i.e., the
SLE susceptibility allele) produced significantly more
OPN serum protein than did individuals negative for this
allele (15). We now extended the analysis to a total of
124 healthy individuals (including the previously re-
ported 50) and to the 156 polymorphism.
The association of OPN serum levels with 1239
was confirmed in the larger panel of healthy subjects. In
particular, individuals carrying allele 1 for 1239 (in
single or in double dose) displayed higher OPN serum
levels than did individuals negative for this allele
(mean  SD of logarithm-transformed values 5.09 
0.527 ng/ml versus 4.79  0.495 ng/ml, corresponding to
a geometric mean of 162.4 ng/ml versus 120.3 ng/ml; P
0.002). A similar trend was observed in individuals
positive for 156-1 (mean  SD of logarithm-
transformed values 4.96  0.536 ng/ml versus 4.86 
0.512 ng/ml, corresponding to a geometric mean of 141.9
ng/ml versus 129.4 ng/ml). However, this difference was
not statistically significant and completely disappeared
when considering only the 1239-1–negative samples
(n  62). Thus, it appears that only the 3 variation has
an influence on the OPN serum level in healthy individ-
uals. In contrast with the findings in controls, no signif-
icant association of OPN serum levels with 1239 or
156 genotypes was detected in the SLE patients
(mean  SD of logarithm-transformed values 5.27
0.57 ng/ml for the 20 1239-1–positive patients versus
5.37  0.55 ng/ml for the 20 1239-1–negative patients,
and 5.29  0.53 ng/ml for the 36 156-1–positive
patients versus 5.56  0.69 for the 4 156-1–negative
patients).
DISCUSSION
The association of OPN gene polymorphisms
with SLE susceptibility was tested in a large group of
Italian patients and controls. Sequence variations were
searched by a systematic screen of the coding regions as
well as the 3-UTR and 2,083 bp of the 5 flanking OPN
regions in 23 patients. This search was designed to
ensure that potentially causative variants were consid-
ered among those tested, given that the SNPs available
in the public database and in the literature may not
include those specifically relevant to SLE. A total of 13
SNPs were detected, of which 5 are described for the
first time herein. Six SNPs (none of which have been
previously tested for association with SLE) were selected
for further testing in a large panel of Italian patients.
Two sequence variations located in the 5 flank-
ing region (156G/GG) and in the 3-UTR (1239A/C)
were significantly associated with the disease. SNP at
position 1239 was in perfect linkage disequilibrium
with the synonymous variation in exon 7 (Ala236Ala),
which was associated with SLE in a group of 81 Amer-
ican individuals (10). Thus, the previously reported
result has been confirmed in a larger and different
population.
A multivariate analysis showed that the effect on
SLE susceptibility of the 2 SNPs in the 5 and 3 regions
was independent of each other, i.e., not a consequence
of linkage disequilibrium between them. Moreover, in-
dividuals carrying susceptibility alleles for both SNPs
had a higher risk of developing SLE than did individuals
carrying susceptibility alleles only at position 156
(Table 6): the risk associated with homozygosity for
susceptibility alleles at both SNPs was 1.7-fold higher
relative to homozygosity only at156, and almost 4-fold
higher relative to the complete absence of susceptibility
alleles. These data suggest a synergism of the 2 sequence
variations for SLE susceptibility, which is consistent with
a growing number of other examples reported in the
literature (31,32), and indicates that both variations
should be tested in any study investigating the role of
OPN in disease etiology. The remaining haplotype back-
ground does not seem to influence the effect of these 2
SNPs.
The perfect linkage disequilibrium between al-
leles at positions 156, 1748, and intron 1 as well as
between 1239, 282, and 750 does not allow us, in
the absence of functional data, to determine which, if
any, of these sequence variations is primarily involved in
SLE susceptibility. The polymorphism in intron 1 does
not seem to have a functional relevance, according to
recently published observations (30). The SNPs in the 5
flanking region may affect the transcription capability of
the OPN promoter by a differential binding of transcrip-
tion factors. Recent evidence suggests that position
156 falls in a putative binding site for a component of
the RUNX family of transcription factors (33). Interest-
ingly, SNPs in RUNX binding sites in 3 different genes
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were recently associated with 3 autoimmune diseases,
namely SLE, psoriasis, and rheumatoid arthritis, sug-
gesting an important role for this family of DNA binding
proteins in autoimmunity (34).
As for the 3 associated SNPs in the 3 part of the
OPN gene, 2 of them, namely, 282T/C and 750C/T,
are synonymous variations located in exons 6 and 7,
respectively. Synonymous variations that modify exonic
splicing enhancer or exonic splicing silencer sites have
been reported to be causative mutations of genetic
diseases (35). However, the involvement of OPN exon 6
and exon 7 synonymous SNPs in this mechanism seems
unlikely, since the 2 known alternatively spliced isoforms
of human OPN involve exons 4 and 5 (36).
The third SNP (1239A/C) is located in the
3-UTR region. This region is strongly implicated in the
regulation of gene expression because it specifically
controls stability, translational activity, and nuclear ex-
port of messenger RNA (mRNA) (37–39). Sequence
variations in the 3-UTR may affect some of these
functions and can be causative mutations of genetic
diseases (38,39). Interestingly, even if this SNP is not
part of sequences known to bind regulative factors, it
falls in an 18-bp sequence conserved in the human,
bovine, ovine, and porcine OPN 3-UTR, suggesting a
possible functional role of this region. Preliminary
mRNA quantitative analysis performed in 3 individuals
heterozygous for 1239A/C and homozygous for all of
the promoter SNPs showed that mRNA carrying the
SLE-associated allele (1239C) was 4.4-fold more ex-
pressed than mRNA carrying 1239A. These data
suggest a possible influence of this SNP in the control of
mRNA stability. Accordingly, the 1239C allele was
significantly associated with a higher serum protein level
in healthy controls, directly relating OPN levels to this
OPN gene variation and to SLE susceptibility. Con-
versely, no association with the baseline protein serum
level was detected for position 156.
Thus, the mechanism by which this polymor-
phism contributes to SLE susceptibility is less clear. We
can speculate that it might be relevant in the regulation
of OPN production in response to the initial immuno-
stimulating trigger. The fact that neither SNP was cor-
related with the protein level in SLE patients could be
explained by an overwhelming effect of the immune
activation in the patients following the initial trigger.
Intriguingly, the 156 susceptibility allele
(156G) was also associated, albeit with borderline
significance (Pcorr  0.046), with development of lymph-
adenopathy in SLE patients. This pattern recalls the
characterization of ALPS as involving autoimmunities
partly similar to SLE and lymphadenopathy, and as
displaying high OPN levels and association with the
1239C allele (the 156 SNP was not evaluated in
ALPS patients [15]). Since OPN favors proliferation and
inhibits death of lymphocytes in vitro (15), it was sug-
gested that OPN acts in synergy with the inherited Fas
defect, which is considered the main cause of ALPS.
This synergy may favor lymphocyte accumulation in the
secondary lymphoid tissues and development of autoim-
munity. A similar synergy might also work in SLE
patients, who do not carry inherited defects of Fas
function, but rather, overproduce a soluble form of Fas
that may inhibit Fas function (40). Alternatively, OPN
might act in synergy with other apoptosis defects not
identified to date in SLE.
In summary, these data strongly suggest that
OPN genetic variations have a key role in building up an
autoimmune-prone background favoring lymphocyte ac-
cumulation in peripheral lymphoid tissues and leading to
the development of autoimmunity. For at least one of
these genetic variations, an association with increased
OPN levels was demonstrated. OPN may exert its pref-
erential effect through its capacity to stimulate prolifer-
ation and inhibit death of lymphocytes (15,41) or
through its capacity to modulate the immune response
by inducing Th1 responses and potentiating polyclonal
activation of B cells (3–5).
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